{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:27:09Z","timestamp":1761895629486},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2013,2,28]],"date-time":"2013-02-28T00:00:00Z","timestamp":1362009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0057856","type":"journal-article","created":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T13:36:39Z","timestamp":1362144999000},"page":"e57856","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts"],"prefix":"10.1371","volume":"8","author":[{"given":"Juan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanxin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shugen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingbo","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binwu","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanlan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,2,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kaushansky K (2009) Determinants of platelet number and regulation of thrombopoiesis. Hematology Am Soc Hematol Educ Program: 147\u201352.","DOI":"10.1182\/asheducation-2009.1.147"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/asheducation-2011.1.215","article-title":"Management of essential thrombocythemia","volume":"2011","author":"F Cervantes","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Skoda RC (2009) Thrombocytosis. Hematology Am Soc Hematol Educ Program: 159\u201367.","DOI":"10.1182\/asheducation-2009.1.159"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.5858\/2006-130-1123-ACMD","article-title":"BCR\/ABL-negative chronic myeloproliferative disorders: JAK2 mutation and beyond","volume":"130","author":"CC Chang","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"ref5","unstructured":"Calzada AA, Pedrini O, Finazzi G, Leoni F, Mascagni P, <etal>et al<\/etal>.. (2012) Givinostat and Hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2 V617FMyeloproliferative Neoplasm patients. Exp Hematol. [Epub ahead of print]."},{"key":"ref6","first-page":"43","article-title":"Splenomegaly in myelofibrosis\u2013new options for therapy and the therapeutic potentialof Janus kinase 2 inhibitors. J Hematol Oncol","volume":"5","author":"J Randhawa","year":"2012"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Santos FP, Verstovsek S (2012) Therapy with JAK2 inhibitors for myeloproliferative neoplasms. Hematol Oncol Clin North Am. [Epub ahead of print].","DOI":"10.1016\/j.hoc.2012.07.008"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"EJ Baxter","year":"2005","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"R Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"C James","year":"2005","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera,essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"RL Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"JAK2 mutation 1849G&gt;T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia","volume":"106","author":"J Jelinek","year":"2005","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"AV Jones","year":"2005","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.molmed.2005.10.003","article-title":"A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects","volume":"11","author":"C James","year":"2005","journal-title":"Trends Mol Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1726-4901(09)70337-5","article-title":"Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"70","author":"HC Hsu","year":"2007","journal-title":"J Chin Med Assoc"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1091\/mbc.E02-06-0342","article-title":"Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain","volume":"14","author":"P Saharinen","year":"2003","journal-title":"Mol Biol Cell"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2005-10-009514","article-title":"Constitutive activation of STAT5 and Bcl-xL overexpression can induceendogenous erythroid colony formation in human primary cells","volume":"108","author":"L Gar\u00e7on","year":"2006","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM199802263380902","article-title":"Expression of Bcl-x in erythroid precursors from patients with polycythemia vera","volume":"338","author":"M Silva","year":"1998","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.5603\/FHC.2011.0037","article-title":"JAK2 mutation status, hemostatic risk factors and thrombophilic factors inessential thrombocythemia (ET) patients","volume":"49","author":"B Soko\u0142owska","year":"2011","journal-title":"Folia Histochem Cytobiol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"PJ Campbell","year":"2005","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2 V617F mutation in essential thrombocythemia","volume":"19","author":"E Antonioli","year":"2005","journal-title":"Leukemia"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1179\/102453309X12473408860226","article-title":"Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders","volume":"14","author":"AL Basquiera","year":"2009","journal-title":"Hematology"},{"key":"ref23","first-page":"336","article-title":"Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia. Platelets","volume":"23(5)","author":"E Arellano-Rodrigo","year":"2012"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"R Tiedt","year":"2008","journal-title":"Blood"},{"key":"ref25","first-page":"993","article-title":"Genotype-phenotype interactions in the myeloproliferative neoplasms. Hematol Oncol Clin North Am","volume":"26(5)","author":"AL Godfrey","year":"2012"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"James C (2008) The JAK2 V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases? Hematology Am Soc Hematol Educ Program: 69\u201375.","DOI":"10.1182\/asheducation-2008.1.69"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"947","DOI":"10.4065\/80.7.947","article-title":"The JAK2 V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis","volume":"80","author":"A Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00277-010-1154-3","article-title":"Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study","volume":"90","author":"F Palandri","year":"2011","journal-title":"Ann Hematol"},{"key":"ref29","first-page":"2599","article-title":"JAK2 V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood","volume":"118(9)","author":"M Panova-Noeva","year":"2011"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood inmyeloproliferative disorders","volume":"107","author":"F Passamonti","year":"2005","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera","volume":"108","author":"E Lippert","year":"2006","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2141.2005.05682.x","article-title":"Mutation studies in CD3+, CD19+ and CD34+ cell fractions inmyeloproliferative disorders with homozygous JAK2(V617F) ingranulocytes","volume":"130","author":"TL Lasho","year":"2005","journal-title":"Br J Haematol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/sj.leu.2404588","article-title":"Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F)","volume":"21","author":"S Hermouet","year":"2007","journal-title":"Leukemia"},{"key":"ref34","first-page":"840","article-title":"Clinical profile of homozygous JAK2 617V&gt;F mutation in patients with polycythemia vera or essential thrombocythemia. Blood","volume":"110(3)","author":"AM Vannucchi","year":"2007"},{"key":"ref35","first-page":"3589","article-title":"Conditional expression of heterozygous or homozygous JAK2 V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115(17)","author":"H Akada","year":"2010"},{"key":"ref36","first-page":"373","article-title":"Clinical significance of the quantification of JAK2 V617F allele burden in classical Ph-negative myeloproliferative neoplasms. Med Clin (Barc)","volume":"139(9)","author":"AE Kerguel\u00e9n Fuentes","year":"2012"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, <etal>et al<\/etal>.. (2012). Development and validation of an International Prognostic Score of thrombosis in WHO-Essential Thrombocythemia (IPSET-thrombosis). Blood. [Epub ahead of print].","DOI":"10.1182\/blood-2012-07-444067"},{"key":"ref38","first-page":"875","article-title":"How to manage essential thrombocythemia. Leukemia","volume":"26(5)","author":"G Finazzi","year":"2012"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0057856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T19:38:56Z","timestamp":1644435536000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0057856"}},"subtitle":[],"editor":[{"given":"Kathleen","family":"Freson","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,2,28]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,2,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0057856","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,28]]}}}